中国畜牧兽医 ›› 2020, Vol. 47 ›› Issue (1): 267-274.doi: 10.16431/j.cnki.1671-7236.2020.01.031

• 基础兽医 • 上一篇    下一篇

伊维菌素长效透皮剂和普通注射剂在家兔体内的药代动力学比较研究

刘营营1, 岳治光2, 吴宁鹏3, 刘珍珍1, 闫亚群1, 张素梅1, 菅复春1, 张龙现1, 王荣军1, 宁长申1   

  1. 1. 河南农业大学牧医工程学院, 郑州 450002;
    2. 河南安进生物技术股份有限公司, 郑州 450002;
    3. 河南省畜牧局, 郑州 450002
  • 收稿日期:2019-07-19 出版日期:2020-01-20 发布日期:2020-01-17
  • 通讯作者: 宁长申 E-mail:nnl1986@163.com
  • 作者简介:刘营营(1992-),女,河南滑县人,博士,研究方向:人兽共患寄生虫病学,E-mail:109622418@qq.com
  • 基金资助:
    国家现代肉羊产业技术体系建设专项资金项目(nycytx-38)

Comparative Study on Pharmacokinetics of Long-acting Transdermal Agents of Ivermectin and Common Injection in Rabbits

LIU Yingying1, YUE Zhiguang2, WU Ningpeng3, LIU Zhenzhen1, YAN Yaqun1, ZHANG Sumei1, JIAN Fuchun1, ZHANG Longxian1, WANG Rongjun1, NING Changshen1   

  1. 1. College of Animal Husbandry and Veterinary Science, Henan Agricultural University, Zhengzhou 450002, China;
    2. Henan Amgen Biotechnology Co., Ltd., Zhengzhou 450002, China;
    3. Henan Provincial Animal Husbandry Bureau, Zhengzhou 450002, China
  • Received:2019-07-19 Online:2020-01-20 Published:2020-01-17

摘要: 为比较研究制备的伊维菌素长效透皮制剂与普通伊维菌素注射剂药物代谢及药效时间,本研究制备伊维菌素含量分别为0.5%、1.0%和1.5%的长效透皮制剂,采用高效液相色谱法检测不同药量相同体积伊维菌素长效透皮制剂和普通伊维菌素注射剂(1.0%)在家兔体内的药代动力学,并通过PKSolver药代动力学处理软件对数据进行分析。结果显示,0.5%、1.0%、1.5%伊维菌素长效透皮剂和1.0%普通注射剂吸收半衰期分别为0.81、0.52、1.02和0.12 d;达峰时间为1.55、0.97、1.62和0.42 d;峰浓度为47.36、72.02、115.30和99.53 ng/mL;消除半衰期为3.61、5.92、5.59和1.79 d;平均滞留时间为5.27、7.37、5.13和2.16 d;药时曲线面积为1 488.70、3 081.98、3 161.20和480.00 ng·d/mL,伊维菌素长效透皮剂体内维持有效药物浓度的时间长达35 d,普通注射剂仅为9 d。结果表明,伊维菌素长效透皮剂效果稳定,可进行更深入的研究。

关键词: 伊维菌素; 长效透皮剂; 药代动力学; 高效液相色谱

Abstract: To compare the drug metabolism and efficacy time of ivermectin long-acting transdermal preparation and ordinary ivermectin injection,the study prepared the long-acting transdermal preparation with ivermectin content of 0.5%,1.0% and 1.5% respectively.The pharmacokinetics of ivermectin long-acting transdermal preparation and common ivermectin injection (1.0%) in rabbits with different dosage and the same volume were detected by HPLC,and the data were analyzed by PKSolver pharmacokinetic processing software.The results showed that the t1/2ka of 0.5%,1.0%,1.5% ivermectin long-acting transdermal agent and 1.0% injection were 0.81,0.52,1.02 and 0.12 d,respectively;The Tmax were 1.55,0.97,1.62 and 0.42 d,respectively;The Cmax were 47.36,72.02,115.30,99.53 ng/mL,respectively;The t1/2ke were 3.61,5.92,5.59 and 1.79 d;The MRT were 5.27,7.37,5.13 and 2.16 d,respectively;The AUC were 1 488.70,3 081.98,3 161.20 and 480.00 ng·d/mL,respectively.The effective concentration of long-acting transdermal agent of ivermectin was maintained for 35 d in vivo and 9 d in general injection.The effect of long-acting transdermal agents of ivermectin was confirmed,which could be further studied.

Key words: ivermectin; long-term transdermal agent; pharmacokinetic; HPLC

中图分类号: